Avacta Group PLC AVCT

Morningstar Rating
GBX57.10 −1.90 (3.22%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

AVCT is trading at a LOCK|DHghMc premium.
Price
£0.59
Fair Value
LOCK|>F^Vg<H
Uncertainty
LOCK|#N Vc<X
1-Star Price
LOCK|!>tNVq>
5-Star Price
LOCK|^r$!v<q
Economic Moat
LOCK|%Z>
Capital Allocation
—

Trading Information

Previous Close Price
GBX59.00
Day Range
GBX57.10–58.00
52-Week Range
GBX48.00–92.00
Bid/Ask
GBX0.00 / GBX0.00
Shares Outstanding
437.63M
Market Cap
GBX24.99B
Volume/Avg
797,066 / 2M

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
2,269.23
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
—

Company Profile

Avacta Group PLC is a clinical-stage life sciences company expanding the reach of potent cancer therapies with the pre-CISION platform. pre-CISION is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate potent warheads in the tumor microenvironment while sparing normal tissues. The company's pipeline consists of pre-CISION peptide drug conjugates (PDC) or Affimer drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing benefits over traditional antibody drug conjugates. The firm has one reportable segment, Therapeutics, which is engaged in the development of novel cancer therapies harnessing its proprietary technology. Geographically, it derives revenue from South Korea.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
75

Valuation

Metric
AVCT
Price/Earnings (Normalized)
—
Price/Book Value
68.51
Price/Sales
2,269.23
Price/Cash Flow
—
Price/Earnings
No chart available

Financial Strength

Metric
AVCT
Quick Ratio
0.95
Current Ratio
0.95
Interest Coverage
−4.86
Quick Ratio
AVCT

Profitability

Metric
AVCT
Return on Assets (Normalized)
−112.85%
Return on Equity (Normalized)
−1,601.77%
Return on Invested Capital (Normalized)
−150.39%
Return on Assets
AVCT

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|nL<w^x^LOCK|d&#d$137B
Regeneron Pharmaceuticals Inc
REGN
LOCK|bVKy?<mLOCK|mp$KR$99B
Moderna Inc
MRNA
LOCK|d>#rL%?LOCK|WN$90B
argenx SE ADR
ARGX
LOCK|M<&!j>@LOCK|>#%$61B
BeOne Medicines Ltd ADR
ONC
LOCK|QWG$VFLOCK|yy&$48B
Royalty Pharma PLC Class A
RPRX
LOCK|LhF<LF<LOCK|!v>?$31B
Incyte Corp
INCY
LOCK|y%r&l?LOCK|mP$25B
Alnylam Pharmaceuticals Inc
ALNY
LOCK|K&?QGNLOCK|QL!P@$22B
BioNTech SE ADR
BNTX
LOCK|WT?W#TmLOCK|mTP$21B
Jazz Pharmaceuticals PLC
JAZZ
LOCK|?@NZJNtLOCK|xs$16B

Sponsor Center